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An Arg present in the third transmembrane domain of
all rhodopsin-like G-protein-coupled receptors is re-
quired for efficient signal transduction. Mutation of this
Arg in the gonadotropin-releasing hormone receptor to
Gln, His, or Lys abolished or severely impaired agonist-
stimulated inositol phosphate generation, consistent
with Arg having a role in receptor activation. To inves-
tigate the contribution of the surrounding structural
domain in the actions of the conserved Arg, an inte-
grated microdomain modeling and mutagenesis ap-
proach has been utilized. Two conserved residues that
constrain the Arg side chain to a limited number of
conformations have been identified. In the inactive
wild-type receptor, the Arg side chain is proposed to
form an ionic interaction with Asp3.49(138). Experimental
results for the Asp3.49(138)3 Asn mutant receptor show a
modestly enhanced receptor efficiency, consistent with
the hypothesis that weakening the Asp3.49(138)-Arg3.50(139)
interaction by protonation of the Asp or by the mutation
to Asn favors activation. With activation, the Asp3.49(138)-
Arg3.50(139) ionic bond would break, and the unre-
strained Arg would be prevented from orienting itself
toward the water phase by a steric clash with Ile3.54(143).
The mutation Ile3.54(143) 3 Ala, which eliminates this
clash in simulations, causes a marked reduction in
measured receptor signaling efficiency, implying that
solvation of Arg3.50(139) prevents it from functioning in
the activation of the receptor. These data are consistent
with residues Asp3.49(138) and Ile3.54(143) forming a struc-
tural motif, which helps position Arg in its appropriate
inactive and active receptor conformations.
The gonadotropin-releasing hormone (GnRH)1 receptor is a
member of the rhodopsin-like G-protein-coupled receptor
(GPCR) family (1, 2). These heptahelical proteins include the
visual opsins and various receptors for neurotransmitters, pep-
tides, and glycoproteins. Activation of these receptors by their
diverse agonists is associated with conformational changes in
the receptor that facilitate a signal-propagating interaction
with G-proteins (3). These conformational changes can involve
relative movement of helices, as reported for rhodopsin (4, 5)
and/or rotation of the helices as found in a constitutively active
adrenergic receptor (6).
Sequence alignment of GPCRs shows that certain amino
acids are highly conserved at corresponding positions within
the putative transmembrane domains (TMD) (7). Transitions
among receptor conformations may reflect dynamic changes in
side chain interactions within the receptor. Two of these con-
served residues have been studied by reciprocal mutation in
the GnRH and serotonin receptors, and the results suggest that
the TMD 2 and 7 side chains have an interdependent role in
receptor activation (8, 9). Most likely several other conserved
side chains also interact to form the skeleton required for the
conformational rearrangements that accompany the transition
between inactive and active receptor states.
The elucidation of the intramolecular interactions and con-
formational changes underlying receptor activation is hindered
by the absence of high resolution structural data for any GPCR.
The available low resolution projection maps of rhodopsin do
not allow inferences about specific side chain interactions (10,
11). A prevalent approach to investigate structure-function
relations of GPCRs is to introduce structural perturbations via
site-directed mutagenesis and to evaluate their effect on recep-
tor phenotype in binding and signal transduction assays (12).
However, determining the phenotype of mutant receptors does
not lead to an unequivocal interpretation concerning the struc-
tural basis of that phenotype (13).
Molecular modeling has facilitated the integration of exper-
imental observations and biophysical data into a mechanistic
scheme for receptor structure and function (12, 14). Structural
and functional details of ligand binding (15, 16) and receptor
activation by agonist complexing (8, 17) and by constitutively
activating mutations (18) have been simulated in such models.
The receptor models can thus provide a rationalization of cur-
rent experimental data within a structural framework in which
to explore the mechanisms underlying the functional perturba-
tions induced by activation. However, caveats concerning the
computational approaches arise from the complexity of these
structures and the relative paucity of pertinent experimental
data at atomic detail. Not surprisingly, given a limited number
of experimentally determined constraints, the proposed models
may exhibit inconsistent interaction patterns. In addition, GPCR
models usually are not studied in the appropriate aqueous/mem-
brane interface environment, making it less likely that the key
side chain interactions are modeled accurately, especially those
involving side chains near or separated by this interface.
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To overcome the limitations inherent in both site-directed
mutagenesis and computational modeling, we have integrated
mutational studies and the application of computational tech-
niques to the study of structural motifs in the receptor that
may constitute functional microdomains. The inferences from
studies of these microdomains, whose proposed structure can
be substantiated by experimental data, are then evaluated in
the context of a whole receptor model. This approach facilitates
the elucidation of a structural basis for the phenotypes induced
by site-directed mutagenesis. The effect of mutations is tested
first in the microdomain models and correlated with the func-
tional effects of site-directed mutant receptors expressed in
mammalian cells. Using this approach, we have recently
mapped precise interactions in segments of the binding pocket
of the serotonin 5HT2A receptor (19).
In the present report, we have applied this approach to study
the interaction pattern of the conserved Arg in TMD 3 in the
GnRH receptor. The conserved arginine Arg3.50 (see “Experi-
mental Procedures” for locus numbering scheme) has been
implicated in the activation of various GPCRs by mutagenesis
studies (20, 21) and by computational modeling (21, 22). An
understanding of the molecular basis for the functional role of
this Arg requires identification of those residues whose specific
interactions determine its orientation within the structure of
the receptor. Given the great conformational flexibility of the
Arg side chain, it is likely that such orienting residues would
form a three-dimensional motif to which we refer as the argi-
nine cage.
Specific partners for Arg3.50 have been proposed, such as the
conserved Asp in TMD 2 (Asp2.50) (21, 22), based on the ration-
ale of a similar conservation pattern and the need to neutralize
a positive charge in a low dielectric environment. However, a
complete exploration of the conformational space of Arg3.50 in
the context of a full molecular model of the receptor is not
attainable with present computational techniques, and several
other candidate interacting residues can be proposed. In par-
ticular, analysis of the conservation pattern centered on Arg3.50
identifies highly conserved residues that could influence the
conformation of Arg3.50. These residues form the consensus
sequence (I/L)XXDRYXX(I/V) (Fig. 1). Arg3.50, Asp/Glu3.49, and
Ile/Val3.54 are present in all cloned GPCRs belonging to the
rhodopsin family, with the exception of the platelet-activating
factor receptor, which has an asparagine residue at position
3.49 (23). In an a-helical environment, the conservation pat-
tern described above forms an envelope of conserved residues
surrounding Arg3.50, consisting in the GnRH receptor of
Ile3.46(135), Asp3.49(138), and Ile3.54(143) (Fig. 2).
To evaluate the role of these various conserved residues in
caging the Arg3.50 side chain in the inactive and active forms of
the receptor, we have performed a complete conformational
exploration of TMD 3 using Monte Carlo simulations (15). The
helical structure and the helix ends of TMD 3 have been ex-
perimentally substantiated by Cys scanning of the D2 receptor
(24) and by spin-labeling studies of rhodopsin, in which the
membrane/aqueous interface has been located between resi-
dues 3.52 and 3.53 (25). For the Monte Carlo simulations, a
novel biphasic solvent model has been developed that repro-
duces the interface between the interior of a protein and a
water environment.2 Using this Monte Carlo approach, the
inferences about the possible caging interactions involving the
conserved Arg have been tested by evaluating computationally
the structural effects of mutations in this TMD 3 domain model
and correlating these results with the functional effects of
site-directed mutagenesis. These studies provide insight into
the role of Arg3.50(139) in sustaining a pattern of interactions
that may occur in the active and inactive forms of the receptor.
EXPERIMENTAL PROCEDURES
Residue Numbering Scheme—The residues in TMDs are numbered
relative to the most conserved residue contained in the helix, as ex-
plained previously (14). On the basis of this scheme, the most conserved
residue in TMD 3, Arg-139, is designated with the index number 3.50
and is hence referred to throughout as Arg3.50(139); the identification of
the preceding Asp is Asp3.49(138).
Computational Methods—The segment of TMD 3 from Cys3.25 to
Thr3.55 was modeled as an a-helix. These helix boundaries, predicted
following methodology described elsewhere (14), are consistent with
recent experimental results for other GPCRs (24, 25). The environment
surrounding the Arg residue in TMD 3 has been investigated in rho-
dopsin and found to consist of two distinct phases: a water phase and a
membrane-embedded helix (25). The environment of Arg3.50(139) in the
helix was assumed to be similar to the environment of residues buried
inside the protein interior, consonant with studies on the known struc-
ture of the photosynthetic reaction center (26), and has been modeled by
a distance-dependent dielectric. To simulate the biphasic environment
in our calculations, the novel mixed solvent model includes a water
phase and a distance-dependent dielectric phase.2 The boundary be-
tween the two phases consists of a plane parallel to the membrane.
TMD 3 was initially positioned perpendicular to the membrane plane at
the midpoint between residues 3.52 and 3.53 following experimental
observations (23) but was allowed to move 6 2.3 Å vertically in the
direction normal to the membrane plane to prevent arbitrary effects
arising from the initial positioning.
To explore the conformational space available for the cytoplasmic
portion of helix 3, Monte Carlo simulations were performed by varying
the torsional angles for residues Val3.44(133) to Thr3.55(144). The variation
of backbone dihedral angles f and c were restrained to 6 20° from their
initial values. Side chain dihedral angles were rotated freely. Extensive
simulations are necessary to reach convergence of the resulting confor-
mations described by the rotamers we analyzed (see below for a descrip-
tion of the four consecutive dihedral angles defining the rotamers).
Thus, between 100 and 400 rounds of independent random simulations
were performed for each TMD 3 construct. In each round, repeated runs
of Monte Carlo-simulated annealing were performed from a starting
temperature of T1 5 2070 K, with a cooling schedule of Tn 1 1 5 0.9 3
Tn and 10,000 steps per temperature to reach 310 K. Between 19 and 76
million conformations were thus sampled for each wild-type and mu-
tant construct. Analysis of the resulting conformations was performed
at T 5 310 K and restricted to backbone conformations within 6 10°
from their initial values to maintain an a-helical conformation.
The conformations of the side chains, in particular the Arg3.50(139)
side chain, are defined by the corresponding dihedral angles x1, x2, x3,
x4. These dihedral angles are classified according to three main rota-
mers: gauche plus (g1) centered on 260° (encompassing angle values
between 2120° and 0°), gauche minus (g2) centered on 160° (between
0° and 120°), and trans (t) centered on 180° (between 120° and 2120°).
Evaluation of the preferred conformations was performed by analyzing
the populations of each side chain rotamer. The rotamer state of the Arg
side chain is defined by the state of each one of its four dihedral angles,
e.g. the propensity of each dihedral angle (x1, x2, x3, x4) to adopt the
(g1, g2, t) configuration. There are 81 possible Arg side chain rotamers,
which were grouped according to their spatial orientation toward spe-
cific residues in TMD 3. The spatial orientation of each Arg3.50(139)
rotamer was inferred from the average values of each of the four
2 F. Guarnieri, manuscript in preparation.
FIG. 1. The conservation pattern of the cytoplasmic side of
TMD 3 is demonstrated in an alignment of several GPCRs.


























dihedrals defining each rotamer.
The Arg-cage microdomain resulting from this conformational anal-
ysis was positioned in the context of a complete model of the transmem-
brane helix bundle of the GnRH receptor (9), constructed to follow the
electron microscopy projection map of rhodopsin (10) using methodolog-
ical steps and approaches described in detail elsewhere (14).
DNA Constructs and Transfection—Procedures for site-directed mu-
tagenesis of the GnRH receptor, subcloning of the receptor coding
region into pcDNA1/Amp and transient receptor expression have been
described previously (27). COS-1 cells transfected with plasmid DNA
were maintained in Dulbecco’s modified Eagle’s medium containing
10% fetal bovine serum. One day after transfection, COS-1 cells were
split from 100-mm plates into two 12-well plates for the functional
assay or into two 24-well plates for the whole-cell binding assay. Mu-
tations of Asp3.49(138) and Arg3.50(139) were done in the mouse GnRH
receptor, whereas mutations of Ile3.46(135) and Ile3.54(143) were generated
in the human GnRH receptor.
Binding and Functional Assays—Binding of GnRH to the wild-type
and mutant receptors was measured at 4 °C in a whole-cell agonist
competition binding assay 72 h after transfection (13). 125I-GnRH-A
((des-Gly10, D-Ala6, GnRH-ethylamide) was used as the label and dis-
placed by increasing concentrations of GnRH. The Kd for GnRH-A was
estimated from homologous competition binding. The radioactivity
bound to membranes or cells was counted in a g-counter, and the
amount of protein per well was determined using the Lowry method
(28). The phosphatidylinositol hydrolysis assay was performed as de-
scribed earlier (27). The binding and concentration-response curves
were fitted using Kaleidagraph software (27). Ki and Bmax values were
determined by using the program LIGAND (29).
Receptor Efficiency—We have developed an empirical representation
for receptor efficiency (Q) using operational models of occupancy and
response (see Equations 1 and 2),
@AR#/Bmax 5 1/~1 1 Kd/@A#! (Eq. 1)
E/Emax 5 1/~1 1 EC50/@A#! (Eq. 2)
where [AR] represents the concentration of ligand-receptor complex, [A]
is the concentration of free ligand, and Emax and Bmax represent the
maximal response and maximal binding, respectively. Receptor effi-
ciency (Q) represents the quantal functional response achieved per
agonist-occupied receptor. To allow comparison of the various mutant
receptors and to accommodate the influence of spare receptors on EC50
values (27), we define receptor efficiency as (see Equation 3),
Q 5 E/@AR# (Eq. 3)
E represents the functional response obtained at a concentration of
occupied receptor [AR] in the presence of agonist concentration [A]
corresponding to the EC50 value for that particular receptor and ago-
nist. For the GnRH receptor constructs, the agonist utilized for calcu-
lating Q is GnRH. Substituting and solving for Q, where [A] 5 EC50,
gives (see Equation 4)
Q 5 ~1/2! 3 @~Kd 1 EC50!/EC50# 3 ~Emax/Bmax! (Eq. 4)
In calculating Q, Ki has been used as an estimate of Kd. The receptor
efficiency values obtained for the various receptor constructs are ex-
pressed relative to the wild-type receptor value.
RESULTS
Computational Simulations of TMD 3 Segment
Surrounding Arg3.50(139)
The GPCRs demonstrate a pattern of conservation among
several residues that are in spatial proximity to Arg3.50(139)
when the cytoplasmic side of TMD 3 is modeled as a regular
a-helix (see Fig. 2). These potential local sites of interaction for
Arg3.50 include the large hydrophobic residue (Ile/Val/Leu) at
position 3.46, the acidic residue at position 3.49, the Tyr (Ser in
the GnRH receptor) at position 3.51, and the b-branched large
hydrophobic residue (Ile/Val) at position 3.54.
The interaction patterns and rotamer positioning of
Arg3.50(139) with respect to these neighboring TMD 3 residues
were explored with Monte Carlo simulations for the wild-type
helix and for various mutant receptors. Many conformations of
the flexible Arg side chain were not attainable due to steric
clashes with the helix backbone. For example, all Arg rotamers
whose x1 5 g2 are unpopulated because of a clash between the
Arg g-methyl and the backbone carbonyl from the preceding
turn of the helix (30).
The most striking observation to emerge from the simula-
tions is the tendency for Arg3.50(159) to form an ionic bond with
Asp3.49(138), as illustrated in Fig. 2B. Nearly half of the
Arg3.50(139) rotamers observed were bound to this aspartic acid
(Table I). As shown in Fig. 3, a variety of Arg conformations
were identified that form the Arg-Asp interaction. Most other
side chains remained in their original orientations throughout
the simulations, consistent with their preferred rotamer popu-
lations in known a-helical structures. Ser and Thr residues
were overwhelmingly (92–99% of rotamers) in the x1 5 g1
conformation due to H-bonding to the backbone carbonyl of the
preceding turn (30, 31). b-Branched residues (Val, Ile, Thr),
except Ile3.54(143), were constrained to one single x1 population
(83–99% of rotamers) due to clashes with the helix backbone
(30). The structural effects of several mutations of the residues
surrounding Arg3.50(139) were studied computationally:
Ile3.46(135)—The side chain at this position is not as well
conserved as the other residues surrounding Arg3.50. Although
Ile is most commonly found at this site, Leu or Met also occur
FIG. 2. Spatial proximity between
the conserved Arg3.50(139)) and the
conserved residues surrounding
it in TMD 3. A, helical net of TMD 3 of
the human GnRH receptor showing
Arg3.50(139) surrounded by conserved resi-
dues. B, three-dimensional computational
model of TMD 3 of the GnRH receptor
showing the spatial proximity of the con-
served residues surrounding the Arg
residue.


























in different receptors. For the simulations, we substituted
Ile3.46(135) with Ala, Val, and Leu to test 1) the functional
relevance of the wild-type side chain (by substituting Ala), 2)
the role of the b-branched character of the residue (by substi-
tuting Val), and 3) the effect of the large hydrophobic side chain
(by substituting Leu). Monte Carlo simulations of all three
mutant constructs showed that the conformational preferences
of the Arg side chain were similar to those found in the wild-
type receptor. Therefore, according to our results, Ile3.46(135)
does not modulate the orientation of Arg3.50(139).
Asp3.49(138)—Monte Carlo simulations were performed for a
mutation of the conserved acidic residue to Asn. By neutraliz-
ing the charge at this locus, this Asp3.49(138) 3 Asn mutant
would weaken the ionic bond between Arg3.50(139) and
Asp3.49(138) observed in simulations of the wild-type receptor.
This mutation was found to significantly affect the conforma-
tional preferences of the Arg side chain (see Table I). In the
Asp3.49(138) 3 Asn mutant, the Arg side chain rarely interacts
with the 3.49 locus (3% of rotamers). Two new orientations
appear populated, as shown in Fig. 4. 1) Arg3.50(139) is oriented
toward positions 3.47–3.51 where it can H-bond to Ser3.47(136)
and Ser3.51(140) (37% of rotamers). 2) Arg3.50(139) is oriented
toward positions 3.53–3.54 where it can be solvated by water at
the cytoplasmic boundaries. Because activation of rhodopsin
has been shown to involve a proton uptake by Glu3.49 (32, 33),
simulations were also performed for the protonated form of the
aspartic acid, termed Asp3.49(138)3 Asp-H. The results yielded
a pattern of preferred conformations very similar to that of
Asp3.49(138) 3 Asn (Table II).
Ser3.51(140)—A Tyr residue most commonly occurs at this
position in other GPCRs. We tested the functional role of this
residue with the mutant construct Ser3.51(140) 3 Ala. Hydro-
gen-bonding between Arg3.50(139) and Ser3.51(140) was observed
in the Asp3.49(138) 3 Asn mutant receptor, but the mutation
Ser3.51(140)3 Ala did not change significantly the orientation of
the Arg side chain relative to the wild-type construct (data not
shown). Evidently, this H-bond is not energetically competitive
with the ionic bond Arg3.50(139)-Asp3.49(138).
Ile3.54(143)—Only Ile or Val residues appear in GPCR se-
quences at this position. Therefore, this locus always contains
a bulky b-branched, hydrophobic side chain. To test the struc-
tural implications of these properties, we substituted this res-
idue by Val, Leu, and Ala. The Val side chain displays similar
structural features as isoleucine, being hydrophobic, bulky,
and b-branched. Leu is hydrophobic and bulky but has a
g-branched side chain. Ala is hydrophobic but neither bulky
nor branched. Analysis of all rotamers populated over 5%,
shown in Table II, indicates that the prevailing interaction for
the wild-type receptor and the three mutants is still the ionic
bond between Arg3.50(139) and Asp3.49(138) (65–80% of rotam-
ers). Although maintaining the same interaction, the individ-
ual rotamer conformations preferred for this interaction vary
among the mutants and with respect to the wild-type receptor
(Table II). Of note, a novel orientation for the Arg side chain
toward residues 3.53–3.54 appears significantly populated in
the Ile3.54(143) 3 Ala mutant (14.3%) but not in the wild-type,
Ile3.54(143) 3 Val, or Ile3.54(143) 3 Leu mutants. In the Ile
3.54(143) 3 Ala mutant, the Arg side chain can be positioned
toward the aqueous cytoplasm, as illustrated in Fig. 5.
Radioligand Binding and Agonist-stimulated Inositol Phos-
phate Accumulation by the Wild-type and Mutant Recep-
tors—To correlate the predicted local structural roles of the
conserved TMD 3 residues with their effect on receptor func-
tion, constructs obtained from the mutation of Arg3.50(139) and
its surrounding conserved residues (see Fig. 2) were tested for
their effects on ligand binding and inositol phosphate accumu-
lation (Table III). The mutation of the Asp3.49(138), Arg3.50(139),
and Ser3.51(140) loci were carried out on the mouse GnRH re-
ceptor, whereas the Ile3.46(135) and Ile3.54(143) mutants were
generated in the human GnRH receptor. Both human and
mouse GnRH receptors have identical sequences in the TMD 3
segment studied. The amino acid substitutions were designed
to test the side chain property conserved at each locus and/or a
specific functional hypothesis derived from the modeling stud-
ies. The results of the radioligand binding and phosphatidyli-
nositol assay and the relative coupling efficiencies of the vari-
ous receptor constructs are summarized in Table III.
Ile3.46(135)—Removal of the Ile side chain by the Ile3.46(135)3
Ala mutation abolished binding and activation. Substitution by
another b-branched residue Ile3.46(135) 3 Val also eliminated
detectable ligand binding and signal transduction. In contrast,
the Ile3.46(135)3 Leu receptor manifested coupling comparable
TABLE I
Preferred conformations of the Arg3.50(139) side chain-based rotamer populations for the wild-type and Asp3.49(138)-modified receptor by mutation
(Asp3.49(138) 3 Asn) or protonation (Asp3.49(138) 3 Asp-H)
Orientation indicates the side chain locus that is in proximity to the Arg3.50(139) head group. All listed values are expressed as the percentage of







Dihedral angles of Arg3.50 side chain Rotamer populations
x1 x2 x3 x4 Wild type Asp3.49Asn Asp3.49Asn-H
Locus 3.49 salt bridge g1 g1 g2 t 11.9 0.0 0.0
Locus 3.49 salt bridge g1 g2 t t 11.1 0.0 1.0
Locus 3.49 salt bridge t g2 g1 g2 6.3 2.8 0.0
Locus 3.49 salt bridge t g2 g2 g1 7.9 0.0 5.1
Locus 3.49 salt bridge t g2 g2 t 8.3 0.1 6.5
Total rotamer populations with side chain of residue
Arg3.50 oriented toward locus 3.49
45.5 2.9 12.6
Locus 3.51 H-bond t t g2 g1 0.5 7.0 5.9
Locus 3.51 H-bond t t t g1 0.0 3.2 11.6
Locus 3.51 H-bond t t g2 t 0.0 12.9 10.3
Locus 3.51 H-bond t t g2 g2 0.0 14.0 13.8
Total rotamer populations with side chain of residue
Arg3.50 oriented toward locus 3.51
0.5 37.1 41.6
Locus 3.54 H2O solvation t g2 t g1 0.0 7.5 0.5
Locus 3.54 H2O solvation t g2 t t 3.2 21.0 6.6
Locus 3.54 H2O solvation t g2 t g2 0.9 0.9 5.8
Total rotamer populations with side chain of residue
Arg3.50 oriented toward locus 3.54
4.1 29.4 12.9


























to that of the wild-type receptor. However, due to poor expres-
sion of the Ile3.46(135)3 Leu receptor (13% of wild-type receptor
Bmax), the calculated value for receptor efficiency for this mu-
tant reveals a 5-fold increase above the value obtained for the
wild-type receptor (Table III). The affinity of this mutant con-
struct for GnRH is comparable to the wild-type receptor. The
restricted pattern of amino acid substitutions that are function-
ally tolerated at the 3.46(135) position is most consistent with
this site being involved in helix-helix packing (see “Discussion”).
Asp3.49(138)—The Asp3.49(138) 3 Ala mutant had no detecta-
ble agonist binding or activation and could not be evaluated.
The more conservative mutation Asp3.49(138) 3 Asn behaved
like wild type in terms of its Ki, EC50, and Emax values (Table
III). However, the lower Bmax (56% relative to wild type) sug-
gests that this construct has a modestly enhanced signaling
efficiency.
Arg3.50(139)—Mutations of Arg3.50(139) to His and Lys yielded
constructs with no detectable binding or activation. The
Arg3.50(139) 3 Gln mutant expressed well and had wild-type
affinity for GnRH but was very poorly coupled (Table III).
Ser3.51(140)—Consistent with the lack of structural effects
observed with mutation of this locus in the computational
simulations, the phenotype of the expressed Ser3.51(140) 3 Ala
mutant receptor was similar to that of the wild-type receptor
(data not shown). This finding is consistent with results re-
ported previously (34).
Ile3.54(143)—The effects of mutating this locus to Val, Leu,
and Ala were examined. In comparison with the wild-type
receptor, the affinity of GnRH was modestly decreased for the
Ala-substituted receptor. The Ile3.54(143)3 Ala receptor showed
a marked reduction in signaling efficiency, whereas the substi-
tutions with Leu or Val were well tolerated (Table III).
DISCUSSION
Arg3.50 is absolutely conserved in all GPCRs, and its substi-
tution in various GPCRs severely affects signal transduction
(20, 21). The pattern of conservation and the effects of muta-
tions make it likely that this side chain serves a key role in
conformational changes and interactions underlying receptor
activation. The results obtained with mutation of this locus in
the GnRH receptor support a crucial role for this Arg in recep-
tor function. Among the mutant receptors studied, only the
construct with a Gln substitution at this site shows any detect-
able signal transduction. Similar results obtained by mutating
the Arg3.50 in the mouse GnRH receptor have been recently
reported (34).
Oliveira et al. (22) proposed a mechanism for receptor acti-
vation in which the change in orientation of this Arg3.50 con-
stitutes an Arg-switch leading to activation of GPCRs, a hy-
pothesis recently expanded by a combination of mutagenesis
and computational simulations on adrenergic receptors (21,
35). The present study has focused on the molecular details of
the microdomains surrounding Arg3.50 by delineating the
neighboring residues that interact with or restrict the position-
FIG. 3. Wild-type R3.50(139) orientations. Three-dimensional model
of TMD 3 of the GnRH receptor illustrating the preferred conformations
of the Arg side chain (purple) in the wild-type construct. Conserved
residues are highlighted by thicker bonds. Note that all populated
rotamer conformations are oriented toward Asp3.49(138), driven by an
ionic bond between Arg3.50(139) and Asp3.49(138).
FIG. 4. Arg3.50(139) orientations in the D3.49(138)N mutant. Three-
dimensional model of TMD 3 of the GnRH receptor illustrating the
preferred conformations of the Arg side chain (purple) in the D3.49(138)N
construct. Conserved residues are highlighted by thicker bonds. Note
that all the populated rotamer conformations are oriented away from
Asn3.49(138). Instead, Arg3.50(139) is oriented either toward Ser3.51(140)-
Ser3.47(136) (37.1%), where it can H-bond to the Ser residues, or toward
the cytoplasm at the level of Ile3.54(143)-Ala3.53(142) (29.4%), where it
would be solvated.


























ing of the Arg side chain.
Computational simulations provided structural hypotheses
for the phenotypes observed with mutagenesis experiments.
When studied mutants display detectable binding and affini-
ties for GnRH similar to that of the wild-type receptor, we
assume that the overall structure of the receptor was not per-
turbed significantly by these mutations. Mutant receptors
without detectable binding also did not show detectable GnRH-
induced signal transduction, suggesting that either the folding
or the intracellular processing of these receptors was disrupted.
The role of all potential Arg-cage side chains studied will be
discussed separately based on the results from the computa-
tional simulations and the measured properties of the mutant
constructs.
Asp3.49(138)—Computational experiments indicate that the
propensity to form an ionic bond between Arg3.50(139) and
Asp3.49(138) constrains the orientation of the Arg side chain.
This constraint is relieved when the simulations are carried out
for the Asp3.49(138) 3 Asn mutant or for a protonated
Asp3.49(138). The results of mutagenesis in the GnRH receptor
and in other receptors suggest that the interaction between
Arg3.50 and Asp3.49 stabilizes the inactive receptor state. In the
TABLE II
Preferred conformations of the Arg3.50(139) side chain based on rotamer populations for the wild-type and Ile3.54(143) mutants to Ala, Leu, and Val
All listed values are expressed as the percentage of total rotamer populations observed for each construct. Only rotamer populations greater than





Dihedral angles of Arg3.50 side chain Rotamer populations
x1 x2 x3 x4 Wild type Ile3.54Ala Ile3.54Leu Ile3.54Val
Locus 3.49 salt bridge g1 g1 g1 t 2.9 6.8 4.1 6.3
Locus 3.49 salt bridge g1 g1 t g1 3.6 18.9 7.3 3.3
Locus 3.49 salt bridge g1 g1 t t 3.5 9.9 7.6 5.6
Locus 3.49 salt bridge g1 g1 g2 t 11.9 2.8 4.7 3.2
Locus 3.49 salt bridge g1 g2 g1 t 1.4 0.0 6.9 0.5
Locus 3.49 salt bridge g1 g2 t t 11.1 5.8 3.3 5.5
Locus 3.49 salt bridge g1 g2 t g2 0.2 0.5 5.2 1.2
Locus 3.49 salt bridge t g2 g1 g1 3.8 2.3 4.2 6.7
Locus 3.49 salt bridge t g2 g1 t 4.3 0.9 8.4 6.5
Locus 3.49 salt bridge t g2 g1 g2 6.3 3.1 5.5 4.5
Locus 3.49 salt bridge t g2 g2 g1 7.9 12.5 19.5 15.5
Locus 3.49 salt bridge t g2 g2 t 8.3 3.0 3.7 16.4
Total rotamer populations with side chain of residue
Arg3.50 oriented toward locus 3.49
65.2 66.5 80.4 75.2
Locus 3.54 H2O solvation t g2 t g1 0.0 12.7 0.0 0.0
Locus 3.54 H2O solvation t g2 t t 3.2 1.6 3.1 5.3
Total rotamer populations with side chain of residue
Arg3.50 oriented toward locus 3.54
3.2 14.3 3.1 5.3
FIG. 5. R3.50(139) orientations in the I3.54(143)A construct. Three-
dimensional model of TMD 3 of the GnRH receptor illustrating the
preferred conformations of the Arg side chain (purple) in the Ile3.54(143)
3 Ala construct. Conserved residues are highlighted by thicker bonds.
Most of the populated rotamer conformations are oriented toward
Asp3.49(138), as observed for the wild-type (Fig. 4), driven by an ionic
bond between Arg3.50(139) and Asp3.49(138). However, in this construct,
Arg3.50(139) is also significantly oriented toward Ala3.54(143) (12.7%),
where it would be solvated in the aqueous cytoplasm.
TABLE III
Binding and activation of wild-type and mutant GnRH receptors
expressed in COS-1 cells
The Ki and Bmax values are obtained from competition binding assays
(mean 6 S.E. from 3–5 experiments). The Emax and EC50 values are
obtained from the phosphatidylinositol hydrolysis experiments
(mean 6 S.E. from 3–5 experiments). Basal activity was unchanged for
all constructs. The mutations of Asp3.49(138) and Arg3.50(139) were gener-
ated in the mouse (m) GnRH receptor, whereas the mutations of
Ile3.54(143) and Ile3.46(135) were made in the human (h) GnRH receptor. u,
undetectable.
Constructs
Competition binding Phosphatidylinositolassay Relativereceptor
efficiencyBmax Ki GnRH Emax EC50
%wt nM %wt nM
h wild type 100 1.4 6 0.2 100 0.3 6 0.1 1
Ile3.54(143)Ala 109 6 9 6.8 6 1.5 69 6 10 9.5 6 1.3 0.2
Ile3.54(143)Leu 25 6 4 3.5 6 1.8 66 6 10 0.8 6 0.3 2.5
Ile3.54(143)Val 64 6 8 1.9 6 1.2 70 6 7 0.3 6 0.1 1.4
Ile3.46(135)Ala u u u u
Ile3.46(135)Leu 13 6 1 3.2 6 1.5 96 6 22 1.2 6 0.1 4.8
Ile3.46(135)Val u u u u
m wild type 100 1.1 6 0.4 100 0.4 6 0.2 1
Asp3.49(138)Ala u u u u
Asp3.49(138)Asn 56 6 5 1.4 6 0.4 98 6 6 0.3 6 0.1 2.9
Arg3.50(139)His u u u u
Arg3.50(139)Lys u u u u
Arg3.50(139)Gln 559 6 112 8.9 6 1.0 68 6 7 65.2 6 7.0 0.04


























a-adrenergic receptor, the mutation Asp3.49 3 Asn leads to
constitutive activation of the receptor (21, 35). We find that
mutation of Asp3.49 3 Asn leads to a modest increase in the
efficiency of GnRH receptor activation similar to the reported
result of the Glu3.49 3 Gln mutation in rhodopsin (33).
In rhodopsin, receptor activation is accompanied by the up-
take of two protons at cytoplasmic sites (32). One site of uptake
has been identified as Glu3.49, based on the lack of proton
uptake by the Glu3.49 3 Gln mutant (32). Thus neutralization
of the 3.49 locus by either protonation or mutation favors the
activated form of the receptor. To rationalize these results in
the structural context of the proposed Arg3.50-Asp3.49 interac-
tion, we performed the relevant computational experiment of
protonating Asp3.49(138) in the GnRH receptor. In the Monte
Carlo simulations, neutralization of the acidic group at position
3.49 either abolished (Asp3.493 Asp) or dramatically decreased
(Asp3.493 Asp-H) the orientation of the Arg side chain toward
the 3.49 locus (Table I). Based on these experimental and
computational findings, we hypothesize that the conserved Arg
side chain is held by Asp3.49(138) through an ionic bond in the
inactive state of the receptor and that receptor activation in-
volves the release of this constraint on the Arg3.50(139) side
chain conformation, most likely by protonation of Asp3.49.
Ile3.54(143)—This locus shows a 100% conservation profile as
a b-branched, bulky hydrophobic residue (Ile or Val). Experi-
mentally, the Ile3.54(143) 3 Val and the Ile3.54(143) 3 Leu mu-
tants were similar or more efficient than the wild-type recep-
tor. The Ile 3.54(143)3 Ala mutant was inefficient in mediating
signal transduction and displayed a much lower receptor effi-
ciency than the wild-type receptor. In simulations, the pre-
ferred orientations of the Arg side chain in the Ile 3.54(143)3 Val
and the Ile 3.54(143) 3 Leu mutants were similar to those ob-
served in the wild-type receptor. However, in the Ile3.54(143) 3
Ala mutant, a new orientation of the Arg side chain was sig-
nificantly populated (14.3%, Table II). Analysis of the new
rotamer conformations that are populated after mutation of Ile
3.54(143)3 Ala provides a rationale for the observed phenotype.
The bulky side chain of an Ile, Leu, or Val residue at this
position would clash with the Arg side chain when this adopts
the rotamer (t, g2, t, g1), as shown in Fig. 6. In contrast, an
Ala at this position lacking the bulky side chain would allow
this unfavorable conformation of the Arg residue, as can be
seen in Fig. 5. According to the membrane-water boundary
determined experimentally for rhodopsin and located between
residues 3.52 and 3.53, the (t, g2, t, g1) rotamer of the Arg
would orient the charged guanidinium group toward the aque-
ous cytoplasm. The strong solvation of the charged Arg side
chain would inhibit it from further participation in any in-
tramolecular interactions. Consequently, the results suggest
that the structural role of Ile3.54 is to restrict the positioning of
Arg3.50 during receptor activation. In the absence of a bulky
side chain at this position, the solvation of Arg3.50 in the cyto-
plasm may prevent it from forming the interactions most con-
ducive to establishing an active receptor state.
Ile3.46(135)—In the simulations, the wild-type receptor and
Ile3.46(135) mutant constructs showed similar orientations of the
Arg side chain and the surrounding residues. Mutagenesis
experiments show that mutation of Ile3.46(135) to either Ala or
Val is not tolerated, whereas substitution by Leu shows in-
creased receptor efficiency as compared with the wild-type
receptor. Both the lack of a local helix 3 effect of mutation of
this locus in computational experiments and the highly re-
stricted pattern of functionally tolerated mutations suggest
FIG. 6. Proposed role of I3.54(143) in caging Arg3.50(139) through a
steric clash. Three-dimensional model of TMD 3 of the GnRH receptor
where R3.50(139) attempts to adopt the (t, g2, t, g1) rotamer configura-
tion oriented toward the C terminus or cytoplasmic boundary of TMD 3
but clashes with Ile3.54(143). Note that in this conformation Arg3.50(139)
reaches the membrane-cytoplasm interface (white line), as determined
for rhodopsin (25), and could thus become solvated.
FIG. 7. Schematic representation of
the human GnRH receptor showing
the position of Asp or Glu residues
within the TMD (black circles), rela-
tive to Arg3.50 (black circle) and the
Arg-cage residues studied (shaded).
Modeling in three dimensions indicates
that Arg3.50 cannot interact with Asp2.61
or Glu2.53 in TMD 2, based on inferences
from an engineered zinc-binding site be-
tween TMD 2 and TMD 3 (positions 2.64
and 3.28) (34). Aspartic acids Asp3.49 and
Asp7.49 are in position to interact with
Arg3.50. Asn2.50 is emphasized because it
is a conserved Asp residue in most GPCRs
and is proposed to interact with Arg3.50
when Asp7.49 is replaced by an Asn in
these receptors.


























that Ile3.46(135) does not form a part of the Arg-cage motif and
may have a role in interhelical interactions not considered in
this study.
Ser3.51(140)—Although there is a possible H-bonding interac-
tion between Arg3.50(139) and Ser3.51(140), the interaction energy
is not competitive with the strong Arg3.50(139)-Asp3.49(138) inter-
action that predominates in the wild-type receptor. Removal of
the H-bonding group of Ser3.51(140) by substitution to Ala pro-
duced no detectable alteration of the functional properties of the
GnRH receptor (32), suggesting that Arg3.50(139) does not interact
with this site or that the energetic contribution of such an inter-
action to the receptor activation mechanism is not significant.
Mechanistic Hypothesis for the Transition from an Inactive to
an Active State of the Receptor—The implications of the pattern
of interactions (e.g. Arg3.50(139)-Asp3.49(138)) and preferred con-
formations of the Arg3.50(139) side chain derived from conforma-
tional analysis on TMD 3 alone were further analyzed in the
context of a seven TMD model of the receptor. Because the
strongest interaction of Arg3.50 is an ionic bond, we explored
whether an alternative charge counterpart (Asp/Glu) could be
found within other TMDs. The Asp or Glu residues present
within the transmembrane domains of the GnRH receptor are
shown schematically in Fig. 7. An acidic counterpart for the
Arg would be expected to share its high degree of conservation
and to reside at the cytoplasmic side of a TMD. However, the
only conserved acidic group in the TMDs of the GnRH receptor
is the Asp3.49(138) in the TMD 3 studied here. There are three
nonconserved acidic residues present in the TMDs of the GnRH
receptor at positions Glu2.53(90) and Asp2.61(98) in TMD 2 and
Asp7.49(319) in TMD 7 (Fig. 7). An interaction of Arg3.50(139) with
Glu2.53(90) or Asp2.61(98) is inconsistent with the geometrical
constraints of an engineered Zn21 binding site reported re-
cently between TMD 2 and TMD 3 for the NK-1 receptor (36).
Therefore these interaction possibilities were excluded. An in-
teraction of Arg3.50(139) with the nonconserved Asp7.49(319) is
possible in the complete model of the transmembrane portion of
the GnRH receptor.
Notably, Asp7.49(319) forms part of a pair of conserved resi-
dues for which modeling and double mutant studies suggest an
involvement in GPCR activation (8, 9). An unusual feature of
the GnRH receptor is the presence of an Asn at position 2.50 in
TMD 2 (Fig. 7) where nearly all other rhodopsin family GPCRs
have an Asp. On the other hand, Asp7.49(319) in the GnRH
receptor is an Asn in most GPCRs. This apparent interchange
of conserved residues suggests that these residues may inter-
act, a hypothesis supported by molecular modeling and double
mutation studies of both the GnRH receptor (9) and the sero-
tonin 5-HT2A receptor (8). These results imply that Asp
7.49(319)
in the GnRH receptor substitutes functionally for the con-
served Asp normally found at the 2.50 locus in other GPCRs
and is therefore a suitable charged counterpart for Arg3.50 in
terms of their high conservation profile. We suggest that one
function of Asp7.49 in the GnRH receptor is to interact with
Arg3.50 in the active state of the receptor. Exploring this pos-
sibility in the context of a model of the GnRH receptor supports
an interchangeable role of Asp7.49(319) and Asn2.50(87) in the
interaction with the Arg residue in TMD 3, as shown in Fig. 8A.
The Arg side chain is capable of extending from TMD 3 toward
TMD 2 and TMD 7, where it can interact simultaneously with
Asp7.49(319) and Asn2.50(87). We hypothesize that during recep-
tor activation, Asp3.49 becomes protonated, and Asp7.49 substi-
tutes for Asp3.49 in forming an ionic interaction with Arg3.50.
In most GPCRs, the active state interaction would occur with
the Arg3.50-Asp2.50 bond as shown in Fig. 8B. Several models of
GPCRs have proposed an interaction of Arg3.50 with the
Asp2.50-Asn7.49 locus (33, 20) but associate this interaction with
the inactive state of the receptor. However, our data and re-
sults from other GPCRs described below support the role of this
interaction with the conserved Asp/Asn pair at the 2.50–7.49
loci in stabilizing the active, not the inactive, receptor confor-
mation. Thus, such a hypothesis is consistent with the finding
in many GPCRs that mutations eliminating the charged char-
acter of Asp2.50, which would be expected to destabilize the
proposed active-state Arg-Asp interaction, either abolish or
significantly decrease receptor activity (37). Furthermore,
spectroscopic experiments in rhodopsin showing that Asp2.50 is
more strongly H-bonded upon activation (38), are also consist-
ent with the proposed interaction between Arg3.50 and Asp2.50
in the active state.
In summary, the experimental and computational results
suggest that the orientation of the highly conserved Arg3.50(139)
side chain is constrained in the inactive receptor state by an
ionic interaction with the neighboring conserved residue
Asp3.49(138). During activation, Asp3.49 becomes protonated,
and the Arg side chain is released. The conserved bulky side
chain of Ile3.54(143) modulates the positioning of the Arg side
chain by keeping it away from the cytoplasmic aqueous medium
and thereby promotes the interaction with Asp7.49 (Asp2.50 in
other GPCRs) that characterizes the active state of the receptor.
Further studies of other structural motifs that have the role of
functional microdomains will allow refinement of these proposed
molecular events underlying receptor activation.
FIG. 8. Three-dimensional model of
TMDs 2, 3, and 7 of the GnRH recep-
tor showing proposed interactions
between Arg3.50(139) and the residues
at positions 3.49–2.50–7.49. A, GnRH
receptor. Arg3.50 interacts with Asp3.49
and the side chains of Asp7.49 and Asn2.50.
B, 5-HT2A receptor. Arg
3.50 interacts with
Asp3.49 and the carbonyls of Asn7.49 and
Asp2.50. Note that the set of interactions
between the Arg residue and the TMD
2-TMD 7 loci in the GnRH receptor can be
mimicked in the 5-HT2A receptor, despite
the reciprocal arrangement of Asn and
Asp at the 2.50 and 7.49 loci.
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